Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts

Questions surrounding a subanalysis of PLATO data showing that AstraZeneca's experimental antiplatelet drug Brilinta (ticagrelor) apparently didn't help North American acute coronary syndrome patients center not on whether the observation is valid, but on what FDA's reaction will be